Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CG Oncology

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Jan 25, 2024 11:38am

71 Views

Post# 35845095

RE:CG Oncology

Irving, Calif.-based CG Oncology (CGON) offered 20 million shares at $19 as it raised $380 million with underwriters Morgan Stanley, Goldman Sachs and Cantor Fitzgerald. Including an additional three million shares to be sold by underwriters, the deal will raise $437 million.

<< Previous

Bullboard Posts

Next >>

Yukon agency detects cyanide near Victoria Gold's Eagle mine